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Antigen (Ag) receptor engagement on lymphocytes triggers a signaling cascade 
that phosphorylates the scaffold protein CARD11 in its inhibitory domain (ID) and 
transforms it from a closed and inactive state into an open and active conformation. This 
conformational change results in disruption of intramolecular interactions, cofactor 
assembly, NF-κB activation and lymphocyte activation. To better understand how 
CARD11’s inhibitory domain regulates these functions, we performed a systematic 
analysis of the 231 residues that comprise the inhibitory domain. We discovered the 
inhibitory domain is made up of multiple operational elements that cooperatively control 
its overall function. Four independent and redundant repressive elements maintain 
CARD11 in the closed conformation and prevent Bcl10 association. A single, contiguous 
inducibility element controls the transition from the closed to open conformation. 
Furthermore, we identified two novel activating elements that demonstrated a greater 
potential for CARD11 hyperactivity than was previously thought. We found that 
lymphoma-associated mutations in CARD11 disrupted intramolecular binding to multiple 
repressive elements, allowing them to bypass the need for inhibitory domain 
phosphorylation. Overall, we uncovered a highly evolved mechanism of modulating 
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The precise and rapid activation of NF-κB activation downstream of antigen 
receptor engagement is important to mount an anti-inflammatory response in T cells and 
B cells (Schulze-Luehrmann and Ghosh, 2006; Wegener and Krappmann, 2007). Central 
to the activation of T cell receptor (TCR) or B cell receptor (BCR) signaling to NF-κB is 
the adaptor molecule caspase-recruitment domain 11 (CARD11) (Egawa et al., 2003; 
Gaide et al., 2002; Jun et al., 2003; Pomerantz et al., 2002; Wang et al., 2002). CARD11 
is a multi-domain scaffold protein, consisting of an N-terminal CARD domain, followed 
by a linker (L1), coiled-coiled domain (CC), an inhibitory domain (ID), PDZ domain, 
another linker (L3), SH3 domain, an additional linker (L4) and a guanylate kinase 
domain (GUK). Upon TCR engagement, membrane proximal kinases initiate a signaling 
cascade that activates protein kinase C θ (PKCθ), which phosphorylates CARD11 in its 
inhibitory domain (Matsumoto et al., 2005; Sommer et al., 2005). This phosphorylation 
event activates CARD11 and, through an as yet unknown mechanism, activates the IκB 
kinases, which phosphorylate the IκB proteins, allowing them to be ubiquitinated and 
degraded. These events culminate in the unmasking of NF-κB’s nuclear localization 
sequence, its translocation into the nucleus and the subsequent transcription of cytokines, 
pro-proliferative and anti-inflammatory genes.  
CARD11 activity is regulated internally though ID-mediated autoinhibition. In the 
resting state, CARD11 is in a closed, inactive conformation mediated by intramolecular 
interactions between the ID and the N-terminal CARD, L1 and CC domains (McCully 
and Pomerantz, 2008). ID phosphorylation neutralizes the ID by triggering a 




domains and allows them to interact with several co-factors such as Bcl10, MALT1, 
TRAF6, the IKK complex and Caspase-8 (Bertin et al., 2001; Che et al., 2004; Gaide et 
al., 2001; McCully and Pomerantz, 2008; Shinohara et al., 2005; Shinohara et al., 2007; 
Wegener et al., 2006). In addition to the phosphorylation of S564 and S657 by PKCθ, it 
is also known that S567 phosphorylation by IKKβ and S577 phosphorylation by an 
unknown kinase play an important role in ID neutralization (Matsumoto et al., 2005; 
Shinohara et al., 2007; Sommer et al., 2005). Besides these modifications, HPK1 
phosphorylation of S563 is necessary for downstream NF-κB activation (Brenner et al., 
2009). 
CARD11’s ID is also modified after NF-κB activation to help downregulate 
signaling. Casein kinase 1 α (CK1α) has been shown to phosphorylate S620 and the 
serine to alanine mutation exhibits sustained NF-κB activation (Bidere et al., 2009). 
Similarly, the S649A mutation prevents phosphorylation by PKCβ and another novel 
kinase and results in enhanced NF- κB signaling (Moreno-Garcia et al., 2009). 
Alternatively, phosphatase PP2A can inhibit CARD11 activity by removing the 
phosphate on S564 (Eitelhuber et al., 2011). Thus, it is increasingly evident that 
CARD11’s ID is a central modulator of CARD11 activity and TCR or BCR signaling 
output. 
The presence of CARD11 mutations in activated B-cell like diffuse large B-cell 
lymphoma (ABC-DLBCL) patients underlies its importance in humans. These mutations, 
found in about 10% of patients, have been characterized as gain-of-function mutations 




Davis et al., 2010; Lenz et al., 2008). Interestingly, these CARD11 hyperactive mutations 
were initially thought to be localized only in the CC domains; however, recent studies 
have uncovered lymphoma-associated CARD11 mutations in both the CARD domain and 
the LATCH domain, a portion of the linker between the CARD and CC with a high 
propensity for developing hyperactive mutants (Bu et al., 2012; Compagno et al., 2009; 
Dong et al., 2011; Lohr et al., 2012; Montesinos-Rongen et al., 2010). Mechanistic 
studies of several of these mutations indicated that they bypass ID-mediated 
autoinhibition by disrupting intramolecular binding (Chan et al., 2013; Lamason et al., 
2010). Additionally, these CARD11 mutants spontaneously associated with Bcl10 
specifically and promoted the nucleation with MALT1, but not other co-factors (Chan et 
al., 2013; Lamason et al., 2010).  
From the CARD11 mutation studies, questions began to emerge about the 
subtleties of the ID mechanism of inhibition. With so many identified lymphoma-
associated CARD11 mutations in the CARD, LATCH and CC domains, we did not 
understand why ID mutants had not been identified. It was also unclear how the ID 
regulated the association of Bcl10 and other co-factors. Here, we performed a systematic 
analysis of the ID to identify functional subdomains that regulate intramolecular binding, 
Bcl10 binding and signaling capacity for NF-κB activation. We describe a highly 















Chapter II: Functional Elements in CARD11’s Inhibitory 











CARD11’s Inhibitory Domain contains multiple, redundant Repressive 
Elements 
In order to reveal the different functional regions of the ID, we first divided the ID 
into approximately six equal portions (Figure 2.2A). Utilizing downstream activation of 
an NF-κB responsive luciferase reporter, Igκ2-IFN-Luc, in CARD11-deficient Jurkat T 
cells as a readout of CARD11 activity, we asked if inhibitory function could be restricted 
to any one of these regions. If this was the case, we would expect its deletion to mimic 
the hyperactivity seen in ΔID. As expected, wild-type murine CARD11 (WT) rescues the 
defect in αCD3 and αCD28-mediated NF-κB activation and Δ441-671 is constitutively 
active even in the absence of stimulation (Figure 2.2B, C). Our results also indicated that 
no single intradomain deletion affected ID function in the basal state, implying that 
multiple, redundant regions of the ID were capable of exerting some repressive function 
(Figure 2.2B, C). Moreover, residues 530-616 were necessary for reversing ID inhibition.  
Of note, the deletion of S657, a previously identified PKCθ phosphorylation site, had no 
effect on ID neutralization (Figure 2.2B, C).  
 We then went on to map the different regions of the ID having some repressive 
function, which we termed repressive elements (REs). They are depicted in Figure 2.1. 
To identify these elements, we took a minimalist approach. In the context of ΔID, we 
sequentially added intradomain regions onto the N-terminus of the ID and assessed which 
regions were capable of repressing the activity of ΔID (Figure 2.3A). The first 90 amino 
acids of the ID, which we named RE1, conferred 4.8 fold repression over ΔID (Figure 




of the ID (Figure 2.4). CARD11 residues 530-610 further repressed CARD11 activity 
four fold, hinting at the presence of another RE among these residues (Figure 2.3B, C).  
 To circumvent the redundancy of the REs, we reversed our sequential addition to 
add C-terminal ID intradomain regions onto ΔID to assess CARD11 inhibition (Figure 
2.5A). Surprisingly, the last 17 residues of the ID displayed constitutive hyperactivity 
more than fivefold greater than that seen with ΔID (Figure 2.5B, C). This hyperactivity 
was indicative of a novel activating element (AE). Our analysis also revealed a clear RE, 
designated RE4, that repressed the hyperactivity of AE almost 100 fold and was 16 fold 
repressed compared to ΔID (Figure 2.5B, C). This RE was restricted to CARD11 residues 
617-641 (Figure 2.6). 
 The redundancies of REs made it difficult to characterize the possible RE between 
CARD11 residues 530-610. Thus, we sought to mutate RE1 and RE4 and reevaluate 
repressive function in our addition analysis. Because CARD11 residues 484-493 
possessed 38 fold repressive potential in RE1, we specifically targeted these residues for 
mutagenesis (Figure 2.4 and Figure 2.7A). By contrast, three or four residue mutations 
covering all 25 amino acids of RE4 were examined (Figure 2.8A). Both RE1 mutations 
tested diminished the repressive abilities of RE1 by at least two fold (Figure 2.7B, C). 
While some RE4 mutants had a modest effect on CARD11 activation, three of the eight 
mutants completely abolished repression (Figure 2.8B, C). M1 and M9 were then chosen 
for further studies of RE1 and RE4, respectively. 
 With RE1 mutated, we repeated our C-terminal ID addition analysis and found 




evidence of a repressive element in these residues was even more compelling in the RE4 
mutant context where it conferred over 300 fold inhibition (Figure 2.9A, D, E). Notably, 
we observed that residues 536-573 had substantial activating capacity. This activity was 
more pronounced in the RE4 N-terminal ID addition analysis, where there was a 30 fold 
increase in activation (Figure 2.9D, E). This data also suggests the full activity of this 
element may extend beyond residue 536.    
 When mapping the boundaries of the newly uncovered repressive element, we 
actually detected two, non-overlapping REs (Figure 2.10A). The CARD11 residues 574-
599, labeled RE2, had over 100 fold repressive capacity (Figure 2.10B, C). This RE was 
further constricted to residues 586-599 (data not shown). The other identified RE, RE3, 
spanned residues 600-610 and was similar to RE2 in its repressive potency (Figure 
2.10B, C).  
Close examination of the sequence of RE2 and RE3 indicated strong sequence 
homology between the two. Both possessed a hydrophobic residue, followed by three 
acidic residues and an asparagine (Figure 2.10A). We hypothesized that RE2 and RE3 
function was dependent on this homologous sequence. To test this possibility, we 
mutated the three acidic residues to basic residues and asked if this abrogated RE2 or 
RE3 function (Figure 2.10A). We discovered that mutating the acidic residues of RE2 or 
RE3 alone was not sufficient to bestow hyperactivity, but that mutating RE2 and RE3 
consecutively achieved hyperactivity at least 75% of that seen in the absence of the two 





Because we wanted to carry out an exhaustive analysis of the ID, we probed for 
extra obscured repressive elements by repeating our N-terminal ID addition assay in the 
presence of simultaneously mutated RE2, RE3 and RE4. This analysis confirmed no 
other repressive elements in the ID (data not shown). Taken together, we discovered four 
independent and redundant repressive elements that could inhibit CARD11 activity. 
  
CARD11’s Inhibitory Domain contains two independent Activating 
Elements 
 Since our initial mapping of RE2 and RE3 hinted at the existence of a second 
activating element, we aimed to isolate this sequence and confirm its activating potential 
(Figure 2.9). Importantly, we wanted to see if the activating element was separable from 
RE2. To this end, we isolated residues 536-585 and ascertained what effect they had on 
CARD11 ΔID activity. Indeed, these residues were sufficient to cause CARD11 
hyperactivity (data not shown). Then, we wanted to determine the minimal region of this 
activating element and found that residues 547-585 formed a de facto activating element 
AE1 (Figure 2.11B, C). These residues possessed 6.5 fold higher activity than ΔID and 
over 600 fold higher activity compared to CARD11 WT (Figure 2.11B, C). In addition, 
we saw that AE1 and AE2 in tandem was slightly more active than either AE alone, 
suggesting some redundancy in activating element function (Figure 2.11B, C). Overall, 
the activity of both AEs together, which was about 800 fold higher than WT and about 
eight fold higher than ΔID, represents the highest level of potential CARD11 activity 





 CARD11’s Inhibitory Domain contains a single Inducibility Element 
 Although it is known that several residues of CARD11 are known to be modified 
upon antigen receptor signaling, we wanted to identify which of these residues was 
necessary for inducing CARD11 activity after stimulation. In order to do this, we re-
examined our intradomain deletions for regions that, when deleted, reduced stimulated 
CARD11 activity. As expected, deletion of amino acids 530-573, which deletes known 
PKCθ phosphorylation site S564 or deletion of 568-616, which deletes known IKKβ 
phosphorylation site S567 resulted in a loss of activity after αCD3 and αCD28 
stimulation (Matsumoto et al., 2005; Shinohara et al., 2007; Sommer et al., 2005) (Figure 
2.2). Similarly, deletion of S577, a known in vivo phosphorylation site, attenuated 
CARD11 induction post stimulation (Matsumoto et al., 2005) (Figure 2.2). Surprisingly, 
deletion of S657 had no effect on inducing CARD11 activity even though it was 
previously characterized as a PKCθ substrate (Matsumoto et al., 2005; Sommer et al., 
2005) (Figure 2.2). This analysis led us to conclude that CARD’s ID neutralization 
occurs through a contiguous inducibility element (IE) that spanned residues 530-616. 
 To further map this IE, we sequentially deleted the ID residues 530-616 from the 
N-terminus and C-terminus and assessed them for their induction of CARD11 activity 
with stimulation (Figure 2.12A). Our data suggested that the induction of CARD11 
requires residues 561-585 (Figure 2.12B, C). Importantly, these residues were sufficient 
to reverse the inhibition of all four repressive elements as seen in Δ530-560 Δ611-616 





CARD11’s Repressive Elements require multiple mutations to abolish 
RE function 
 With so many repressive elements embedded within the ID, we wanted to better 
understand how they functioned together with both activating elements and the 
inducibility element. To do this, we first mutated all four repressive elements in the full-
length CARD11 context (Figure 2.13A). We expected that destroying all RE function in 
the ID would bypass the need of the inducibility element and result in CARD11 basal 
activation equivalent to that of having two activating elements. Instead, we saw that 
mutating all four REs simultaneously only resulted in activity similar to that of deletion 
of the entire ID (Figure 2.13B, C).  
Because our mutational analysis of RE4 was performed only in the context of 
AE2, we hypothesized that the presence of other ID sequences may necessitate the need 
of supplementary mutation in RE4 to completely diminish its repressive function in the 
full-length context. Our initiation RE4 mutational analysis suggested multiple possible 
secondary mutations from which to choose (Figure 2.8B, C). M5 was chosen as the 
second site RE4 mutation because it had a substantial effect on RE4 repression without 
being adjacent to M9, insinuating that this mutation might function by a different 
mechanism from M9 (Figure 2.8B, C). The quadruple RE mutant construct with two RE4 
mutations did, in fact, increase CARD11 activity fivefold, making it as active as AE2 
(Figure 2.13B, C). This result indicated that this version of the quadruple RE mutant still 




Since our RE1 mutant analysis simply tested for the ability to destroy intrinsic 
repression, it did not assay for repression of other ID elements. The limitation of that 
analysis led us to test if a second RE1 mutation could boost quadruple RE mutant 
activity. Hence, we tested two additional RE1 mutants M13 and M14 for their ability to 
increase quadruple RE mutant activity (Figure 2.13B, C). We observed that two 
mutations in RE1, one mutation in RE2, one mutation in RE3 and two mutations in RE4 
for a total of six mutations of 28 total residues in the ID resulted in about 800 fold 
increase in activity compared to WT and about 8 fold higher when compared to ΔID 
(Figure 2.13B). Hence, this version of the quadruple RE mutant reached levels of activity 
similar to that of both activating elements together. From hereon forward, we will refer to 
this construct as the quadruple RE mutant.  
 
CARD11’s Repressive Elements cooperate to repress downstream 
signaling to NF-κB 
 Because of the discrepancy between the effects of RE1 and RE4 mutations in a 
minimal context and the full-length context, we sought to characterize what effects all the 
RE mutations would exert on CARD11 activity in the full-length context. To do this, we 
designed CARD11 ID single, double and triple RE mutant combination constructs 
(Figure 2.14A). The activities of these CARD11 variants would attest to how the REs 
function in combination with AE1 and AE2. Not surprisingly, we found that mutating 
each RE alone had little to no effect on CARD11 activity, confirming the redundancy of 




about three fold, the most of all the single RE mutants (Figure 2.14B, C). This finding 
suggests that RE4 may be the strongest repressor. We also asserted that no RE affected 
CARD11’s inducibility (Figure 2.14B). 
 Similar to the single RE mutants, most double RE mutants were relatively 
repressed. All the double mutants increase CARD11 activity at least four fold over WT; 
however, the RE1 and RE4 double mutant increased downstream NF-κB activity almost 
70 fold (Figure 2.14D, E and Table 2.4). This result indicated that two REs are sufficient 
to mostly inhibit CARD11 activity and that RE1 and RE4 are the two most potent REs. 
 Triple RE mutants were viewed from the perspective of how much a single, intact 
RE could contribute to overall CARD11 inhibition. Unexpectedly, all triple RE mutants 
were at least as active as ΔID (Figure 2.14F, G and Table 2.4). In the full-length context, 
a single RE was insufficient to inhibit CARD11 activity. This analysis also confirmed 
that RE4 was the most potent RE, followed by RE1. Altogether, these results imply that 
the REs work together to repress CARD11. 
  
Bcl10 association is regulated by multiple Repressive Elements 
 After determining the relative contributions of each RE to regulate CARD11 
activity, we asked how each RE regulated the association of co-factors. Bcl10 was of 
particular interest because its association was sufficient to generate hyperactivity in 
several previously described lymphoma-associated CARD11 variants (Chan et al., 2013; 
Lamason et al., 2010). Therefore, we specifically examined how each RE affected Bcl10 




level of Bcl10 association was similar to that of ΔID (Figure 2.15). Furthermore, no 
single RE mutation significantly upregulated Bcl10 association (Figure 2.15A). In 
contrast, all double RE mutants having RE1 mutated showed appreciable levels of Bcl10 
association compared to WT CARD11 (Figure 2.15B). Likewise, having RE1 mutated 
with any two other REs bound to Bcl10 as well as the quadruple RE mutant and ΔID 
(Figure 2.15C). Thus, RE1 was the major contributor to prevent Bcl10 association. 
Nevertheless, the other REs cooperatively regulated Bcl10 binding (Figure 2.15B, C). 
Curiously, the degree of Bcl10 association did not correlate with the level of CARD11 
activity. 
  
CARD11’s Repressive Elements synergize to control intramolecular 
binding 
  Another possible mechanism by which the REs may function is by modulating 
intramolecular binding. To determine if any RE functioned by regulating binding to other 
regions of CARD11, we first generated an N-terminal Flag-GST-tagged ID. If an RE 
mutant disrupted intramolecular binding sites, it would allow a full-length WT ID 
expressed in trans to bind the inherent RE binding targets. As predicted, mutating all four 
REs markedly increased binding to WT ID in trans (Figure 2.16). A single RE did not act 
as the only determinant of conformational state because no single RE mutant was able to 
bind the ID in trans at appreciable levels (Figre 2.16A). Unexpectedly, mutating two RE 
mutants was sufficient to detect disruptions in intramolecular contacts (Figure 2.16B). All 




there was a discernible difference in ID binding for RE combination mutants having a 
WT or mutant RE1, it appeared that RE1 was the dominant player in regulating CARD11 
conformation (Figure 2.16). Our data also demonstrates the synergistic effect of the REs 
on altering intramolecular binding. 
 
Repressive Elements bind differential CARD11 intramolecular targets 
 In order to ascertain the binding site for each RE, we first assayed whether a 
single RE tetramer could mediate binding to ΔID, which is constitutively in the open 
conformation. We found that all four RE tetramers were sufficient to bind ΔID to some 
extent (Figure 2.17). The extremely weak binding of RE4 led us to believe its binding 
target may be within the ID itself. In order to reveal novel intramolecular RE targets 
within the ID, we investigated whether any RE could bind its corresponding full-length 
single RE mutant. Because the single RE mutant lacked the ability to bind its respective 
intramolecular target, these targets would be free to bind the RE tetramer in trans. We 
saw that RE4 tetramer was unable to bind the single RE4 CARD11 mutant, suggesting 
that it does not bind within the ID and it is a weak contributor to maintaining 
intramolecular contacts. The lack of binding of the other REs to their respective single 
RE CARD11 mutants in this assay hinted at redundant RE binding to each CARD11 
target (Figure 2.17).  
 Though all our data so far suggested that all four REs contributed to 
intramolecular binding, we hypothesized that each RE would bind differentially and that 




identify the CARD11 domain targets of each RE, we tested binding of the three strongest 
REs to bind a panel of CARD11 double-deletion variants where each domain of 
CARD11 was deleted simultaneously with the ID deletion. Deletion of the coiled-coiled 
domain (CC) and the guanylate kinase domain (GUK) diminished binding of RE1 
tetramers (Figure 2.18A). Interestingly, this analysis revealed the linker between PDZ 
and SH3 domains (L3) and SH3 domains were inhibitors of RE1 tetramer binding (Figure 
2.18A). RE2 tetramer binding to ΔID required the CARD domain, the linker between the 
CARD domain and the CC domain (L1) and, to a lesser extent, the CC domain (Figure 
2.18B). The RE3 tetramers had a unique domain requirement for binding to ΔID 
compared to RE1 and RE2 as it only required the CARD domain and the CC domains 
(Figure 2.18C). Thus, each RE has a distinct target binding profile.  
 
Lymphoma-associated, gain-of-function CARD11 mutations disrupt 
binding of at least two Repressive Elements 
Based on the partially redundant binding targets of the REs, we speculated that 
lymphoma-associated single point mutations in CARD11’s CARD, LATCH or CC 
domains disrupted binding to multiple REs allowing them to bypass ID neutralization and 
lead to hyperactive CARD11. Because all of the gain-of-function CARD11 mutants were 
at least as active as the most repressed double RE mutants (Chan et al., 2013; Lamason et 
al., 2010), we expected that the lymphoma-associated mutants C49Y, F97Y, G123D, 
F130I and L232LI would reverse the effects of at least two REs. Interestingly, RE1 




binding did not require the LATCH domain (Figure 2.18A, Figure 2.19A). As 
anticipated, both CARD mutants C49Y and F97Y and both LATCH mutants G123D and 
F130I, but not the CC mutant L232LI decreased RE2 tetramer binding (Figure 2.18B, 
Figure 2.19B). RE3 tetramer binding was compromised by mutations in the CARD, 
LATCH and CC domains despite only requiring the CARD and CC domains for binding 
(Figure 2.18C, Figure 2.19C). Indeed, all five oncogenic mutants tested at least partially 
disrupted binding to two REs with four of the five mutants obstructing binding to all 
three REs (Figure 2.19).   
 
Experimental Procedures 
Cell lines and expression constructs 
HEK 293T and human Jurkat T cell lines were cultured as previously described 
(McCully and Pomerantz, 2008).  
pcMycCARD11 WT, ΔID, ΔID double deletions, ΔID C49Y, ΔID F97Y, ΔID 
G123D, ΔID F130I and ΔID L231LI were described previously (Chan et al., 2013; 
Lamason et al., 2010; McCully and Pomerantz, 2008). Various CARD11 deletion 
constructs were cloned by standard molecular biology techniques and sequence verified. 
All ID deletion constructs along with their corresponding amino acid linkers are listed in 
Table 2.1. Mutations were introduced into CARD11 by PCR or by QuikChange Site-
Directed Mutagenesis (Stratagene) using the primers listed in Table 2.2 and are described 




To generate pEBB-Flag-GST-ID, a DNA fragment of CARD11 corresponding to 
CARD11 amino acids 441-671 was cloned into pEBB in frame with an N-terminal Flag 
tag and GST derived from pEBG (McCully and Pomerantz, 2008). pEBB-Flag-GST is a 
variant of the above construct that encodes a stop codon after GST. To generate Flag-
GST-RE multimers, the full-length ID in pEBB-Flag-GST-ID was replaced with four 
copies of the DNA encoding RE1, RE2, RE3 or RE4 corresponding to CARD11 residues 
441-493, 586-599, 600-610 or 617-641, respectively.  
 
HEK 293T protein expression assay 
 Cells were plated at 5x10
5
 cells in 2ml media onto each well of a 6-well plate 24 
hours prior to transfection. Cells were transfected with 200ng pCSK-LacZ, 1500ng Igκ2-
IFN-Luc and up to 1300ng of expression construct, totaling 3μg DNA. In each 
experiment, samples were supplemented with empty pcDNA3 vector to keep the total 
amount of DNA per transfection constant. The media was changed 22-25 hours post 
transfection and harvested 40-42 hours post transfection. Cells were lysed in 500μl lysis 
buffer (Promega) on ice. Cells were scrapped from the plate and incubated with lysis 
buffer on ice at least 10 minutes before cell debris was cleared by centrifugation 17,970 x 
g for 5 min at 4°C. Three microliters of lysate was used to measure β-galactosidase 
activity in a chemiluminescent β-Gal reporter gene assay (Roche) according to the 
manufacturer's instructions. Chemiluminescence was measured by a luminometer (Perkin 
Elmer TR717 or Berthold Technologies TriStar LB 941 Multimode Microplate Reader) 




lysates for transfection efficiency and recovery. Normalized lysates were resolved on an 
8% SDS-PAGE gel, transferred to polyvinylidene difluoride membrane and analyzed by 
Western blot with anti-myc (sc-40; Santa Cruz) antibodies for relative expression. 
 
Determination of CARD11 activity in Jurkat T cells 
The production of stable CARD11 knockdown Jurkat T cells was performed as 
previously described, except that polybrene was excluded from the infection (McCully 
and Pomerantz, 2008). MISSION Non-Target shRNA Control Vector (Sigma SHC002; 
sense sequence: 5’ CAACAAGATGAAGAGCACCAA 3’; loop sequence: 5’ CTCGAG 
3’) was used as a control. CARD11 knockdown Jurkats were transiently transfected with 
Igκ2-IFN-Luc, pCSK-LacZ and pcCARD11 variants, stimulated and harvested as 
described previously (McCully and Pomerantz, 2008). All results shown are the average 
(±std. dev.) of triplicate samples from a single experiment, representative of two or three 
that were performed.  
 
HEK 293T Immunoprecipitations 
  Immunoprecipitations were performed as previously described, except for 
the following (Chan et al., 2013). At 40-42 hours post transfection, cells were harvested 
in 500μl immunoprecipitation lysis buffer (IPLB), incubated on ice 10 minutes, scrapped 
off and centrifuged at 17,970 x g for 5 minutes at 4°C. Eleven microliters of lysate was 
reserved for Western blot analysis and 440 μl lysate used for immunoprecipation with 




(sc-40; Santa Cruz) and anti-FLAG (M2; Eastman Kodak IB13026 or Sigma F1804) 
antibodies as described previously (Chan et al., 2013). Results shown are the 
representative of two or three assays that were performed.  
 
HEK 293T Glutathione Sepharose Pull-down  
Cells were plated at 5x10
5
 cells per well in 6-well plates 24 hours prior to 
transfection. Cells were transfected using the calcium phosphate method with up to 
1400ng Flag-GST variants and up to 750ng CARD11 variants. In each experiment, 
additional pcDNA3 and pEBB vectors were transfected such that each well was 
transfected with equal amounts of pcDNA3 vector and pEBB vector and totaled 2μg 
DNA. Media was changed 22-25 hours post transfection and harvested as described 
previously, except as follows (McCully and Pomerantz, 2008). Cells were lysed in 500μl 
IP Lysis Buffer, precleared twice for 30 minutes with 10μl Protein G Sepharose Fast 
Flow (GE Healthcare) with 4°C rotation. From the precleared lysate 2% or 3% of lysate 
was reserved for input. The remaining lysate was incubated with 10μl bed volume of 
glutathione-Sepharose (GE Healthcare) for 3 hours at 4°C with rotation. Samples were 
washed and analyzed as described previously (McCully and Pomerantz, 2008). Western 
blotting was completed using anti-myc (Santa Cruz, sc-40) and anti-GST (Santa Cruz, sc-













Names Linker Mutation Amino Acid Mutations 
Δ441-671 ΔID RS —  
Δ441-671 Δ5'-3' TG —  
Δ441-488 Δ5'-A TGRD —  
Δ483-535 ΔA-B RKTGKR —  
Δ530-573 ΔB-C DNTGDR —  
Δ568-616 ΔC-D RRTGRD —  
Δ611-654 ΔD-E DKTGKD —  
Δ649-671 ΔE-3' RDTG —  
Δ483-671 ΔA-3' RKTG —  
Δ530-671 ΔB-3' DNTG —  
Δ568-671 ΔC-3' RRTG —  
Δ611-671 ΔD-3' DKTG —  
Δ504-671 ΔA2-3' TG —  
Δ494-671 ΔA1-3' TG —  
Δ441-459                
Δ494-671 
Δ5'-5'1          
ΔA1-3' 
TG/                        
TG 
—  
Δ441-469                
Δ494-671 
Δ5'-5'2            
ΔA1-3' 
TG/                       
TG 
—  
Δ441-478            
Δ494-671 
Δ5'-5'3           
ΔA1-3' 
TG/                       
TG 
—  
Δ441-486           
Δ494-671 
Δ5'-A          
ΔA1-3' 
TG/                       
TG 
—  
Δ494-671 ΔA1-3'+      
mut A 
TG M1 483 SPEDSK 488: RKTGRD  
Δ494-671 ΔA1-3'+       
mut YFLPY 
TG M2 489 YFLPY 493: ADRKA 
Δ441-535 Δ5'-B TGKR —  
Δ441-573 Δ5'-C TGDR —  
Δ441-616 Δ5'-D TGRD —  







Names Linker Mutation Amino Acid Mutations 
Δ441-616           
Δ624-654 
Δ5'D         
ΔD1-E 
TGRD/            
TGKD 
—  
Δ441-616       
Δ633-654 
Δ5'D             
ΔD2-E 
TGRD/          
TGKD 
—  
Δ441-616           
Δ642-654 
Δ5'D           
ΔD3-E 
TGRD/          
TGKD 
—  
Δ441-623            
Δ649-654 
Δ5'-D1        
+mut E 
TG/            
RDTGKD 
—  
Δ441-632          
Δ649-654 
Δ5'-D2          
+mut E 
TG/          
RDTGKD 
—  
Δ441-641            
Δ649-654 
Δ5'-D3         
+mut E 
TG/            
RDTGKD 
—  
Δ441-616 Δ5'-D+        
mut GPPS 
TGRD M3 617 GPPS 620: WQHK 
Δ441-616 Δ5'-D+        
mut IHS  
TGRD M4 621 IHS 623: RFR 
Δ441-616 Δ5'-D+        
mut SSS 
TGRD M5 624   SSS  626: RRR 
Δ441-616 Δ5'-D+       
mut SHQ 
TGRD M6 627   SHQ  629: RFA 
Δ441-616 Δ5'-D+        
mut SEG 
TGRD M7 630   SEG  632: RRW 
Δ441-616 Δ5'-D+        
mut LDA 
TGRD M8 633   LDA  635: RKR 
Δ441-616 Δ5'-D+       
mut YDL 
TGRD M9 636   YDL  638: AKR 
Δ441-616 Δ5'-D+       
mut EQV 
TGRD M10 639   EQV  641: RAK 
Δ530-671 ΔB-3'+         
mut A 
DNTG M1 483 SPEDSK 488 : 
RKTGRD  
Δ568-671 ΔC-3'+         
mut A 
RRTG M1 483 SPEDSK 488 : 
RKTGRD  
Δ611-671 ΔD-3'+            
mut A 








Names Linker Mutation Amino Acid Mutations 
Δ441-573            
Δ611-616 
Δ5'C+          




M9 636   YDL  638: AKR 
Δ441-535            
Δ611-616 
Δ5'B+          
mut D+             
mut YDL 
TGKR/   
DKTGRD 
M9 636   YDL  638: AKR 
Δ441-488           
Δ611-616 
Δ5'A+         
mut D+           
mut YDL 
TGRD/       
DKTGRD 
M9 636   YDL  638: AKR 
Δ441-573 Δ5'-C+       
mut YDL 
TGDR M9 636   YDL  638: AKR 
Δ441-573           
Δ600-616 
Δ5'-C             
ΔC4-D+           
mut YDL 
TGDR/       
AGRD 
M9 636   YDL  638: AKR 
Δ441-599            
Δ611-616 
Δ5'-C4+        
mut D+         
mut YDL 
TG/         
DKTGRD 
M9 636   YDL  638: AKR 
Δ441-573 Δ5'C+              
mut EED+     
mut YDL 
TGDR M9, M11 636   YDL  638: AKR                                     
593   EED   595: RRR 
Δ441-573 Δ5'C+           
mut DDE+        
mut YDL 
TGDR M9, M12 636   YDL  638: AKR                              
607   DDE   609: RRR 
Δ441-573 Δ5'C+         
mut EED+         
mut DDE+      
mut YDL 
TGDR M9, M11, 
M12 
636   YDL  638: AKR                                    
593   EED   595: RRR                               
607   DDE   609: RRR 
Δ441-546              
Δ586-671 
Δ5'B2             
ΔC2-3' 
TG/                        
AG 
—  
Δ441-546               
Δ586-654 
Δ5'B2           
ΔC2-E 
TG/                 
AGKD 
—  
Δ530-535             
Δ611-616 
mutB+D DNTGKR/          
DKTGRD 
—  
Δ530-560               
Δ611-616 
ΔB-B4          
+mutD 









Names Linker Mutation Amino Acid Mutations 
Δ530-567             
Δ611-616 
ΔB-B5          
+mutD 
DNTG/        
DKTGRD 
—  
Δ530-535              
Δ586-616 
mutB+       
ΔC2-D 
DNTGKR/    
AGRD 
—  
Δ530-535             
Δ579-616 
mutB+           
ΔC1-D 
DNTGKR/         
AGRD 
—  
Δ530-560             
Δ586-616 
ΔB-B4            
ΔC2-D 






















Name2 Amino Acid Mutations 
M1                                         
M11                                  
M12                                    
M9 
mut A+             
mut EED+                       
mut DDE+          
mut YDL 
483 SPEDSK 488 : RKTGRD                             
593   EED   595: RRR                                   
607   DDE   609: RRR                                       
636   YDL  638: AKR 
M1                                             
M11                                     
M12                                  
M5                                
M9 
mut A+             
mut EED+       
mut DDE+           
mut SSS+          
mut YDL 
483 SPEDSK 488 : RKTGRD                           
593   EED   595: RRR                                    
607   DDE   609: RRR                                    
624   SSS  626: RRR                                   
636   YDL  638: AKR 
M13                           
M1                                   
M11                                
M12                           
M5                                    
M9 
mut Q+             
mut A+                        
mut EED+                   
mut DDE+               
mut SSS+             
mut YDL 
460 QNLGDTSPRT 469: VTYMKQWAEL          
483 SPEDSK 488 : RKTGRD                         
593   EED   595: RRR                                 
607 DDE   609: RRR                                   
624   SSS  626: RRR                                        
636   YDL  638: AKR 
M14                                 
M1                                   
M11                                 
M12                                
M5                                   
M9 
mut N+          
mut A+                      
mut EED+                  
mut DDE+                  
mut SSS+                  
mut YDL 
470 NGQEADDS 477: TIARMKKF                   
483 SPEDSK 488 : RKTGRD                         
593   EED   595: RRR                                  
607 DDE   609: RRR                                    
624   SSS  626: RRR                                      
636   YDL  638: AKR 
M13                                  
M1 
re1  
RE2                
RE3              
RE4 
mut Q+              
mut A 
460 QNLGDTSPRT 469: VTYMKQWAEL 
483 SPEDSK 488 : RKTGRD  
M11 RE1                 
re2                        
RE3               
RE4 
mut EED 593   EED   595: RRR 
M12 RE1              
RE2                
re3                
RE4 









Name2 Amino Acid Mutations 
M5                                     
M9 
RE1   
RE2              
RE3                 
re4 
mut SSS+              
mut YDL 
624   SSS  626: RRR                                    
636   YDL  638: AKR 
M13                                  
M1                                   
M11 
re1         
re2     
RE3            
RE4 
mut Q+                
mut A+                
mut EED 
460 QNLGDTSPRT 469: VTYMKQWAEL 
483 SPEDSK 488 : RKTGRD                           
593   EED   595: RRR 
M13                                  
M1                                    
M12 
re1   
RE2     
re3                   
RE4 
mut Q+                   
mut A+                   
mut DDE 
460 QNLGDTSPRT 469: VTYMKQWAEL       
483 SPEDSK 488 : RKTGRD                          
607   DDE   609: RRR  
M13                               
M1                                     
M5                                  
M9 
re1       
RE2        
RE3           
re4 
mut Q+            
mut A+            
mut SSS+                
mut YDL 
460 QNLGDTSPRT 469: VTYMKQWAEL       
483 SPEDSK 488 : RKTGRD                          
607   DDE   609: RRR                                    
636   YDL  638: AKR  
M11                                
M12 
RE1       
re2                     
re3                           
RE4 
mut EED+           
mut DDE 
593   EED   595: RRR                                       
607   DDE   609: RRR 
M11                                      
M5                                       
M9 
RE1    
re2     
RE3                    
re4 
mut EED+         
mut SSS+             
mut YDL 
593   EED   595: RRR                                    
624   SSS  626: RRR                                  
636   YDL  638: AKR 
M12                               
M5                                 
M9 
RE1       
RE2         
re3                           
re4 
mut DDE+           
mut SSS+               
mut YDL 
607   DDE   609: RRR                                   
624   SSS  626: RRR                                        
636   YDL  638: AKR 
M13                                
M1                                  
M11                                  
M12 
re1        
re2   
re3    
RE4 
mut Q+             
mut A+          
mut EED+             
mut DDE 
460 QNLGDTSPRT 469: VTYMKQWAEL 
483 SPEDSK 488 : RKTGRD                               
593   EED   595: RRR                                  









Name2 Amino Acid Mutations 
M13                                
M1                                  
M11                             
M5                                    
M9 
re1         
re2      
RE3          
re4
mut Q+           
mut A+               
mut EED+          
mut SSS+       
mut YDL 
460 QNLGDTSPRT 469: VTYMKQWAEL 
483 SPEDSK 488 : RKTGRD                       
593   EED   595: RRR                                   
624   SSS  626: RRR                                   
636   YDL  638: AKR 
M13                                         
M1                                         
M12                             
M5                                    
M9 
re1
RE2   
re3           
re4
mut Q+              
mut A+          
mut DDE+           
mut SSS+      
mut YDL 
460 QNLGDTSPRT 469: VTYMKQWAEL 
483 SPEDSK 488 : RKTGRD                       
607   DDE   609: RRR                                   
624   SSS  626: RRR                                       
636   YDL  638: AKR 
M11                              
M12                                  
M5                                    
M9 
RE1           
re2             
re3          
re4 
mut EED+               
mut DDE+                     
mut SSS+             
mut YDL 
593   EED   595: RRR                                    
607 DDE   609: RRR                                           
624   SSS  626: RRR                                     




Table 2.4: Relative activities of CARD11 full-length RE mutants. 





WT 1.000 873.2 
Δ441-671 96.85 9.015 
re1 re2 re3 re4 873.2 1.000 
   re1 re2  re3 RE4 123.2 7.086 
re1 re2  RE3 re4 571.7 1.527 
re1 RE2  re3 re4 535.7 1.630 
RE1 re2 re3 re4 222.2 3.930 
   re1 re2  RE3 RE4 3.929 222.3 
re1 RE2 re3 RE4 11.52 75.77 
re1 RE2 RE3 re4 63.29 13.80 
RE1 re2 re3 RE4 3.837 227.6 
RE1 re2 RE3 re4 16.78 52.05 
RE1 RE2 re3 re4 10.94 79.84 
   re1 RE2 RE3 RE4 1.107 789.0 
RE1 re2 RE3 RE4 1.133 770.6 
RE1 RE2 re3 RE4 1.158 754.3 
RE1 RE2 RE3 re4 2.635 331.4 
   1 Fold Basal Activity Relative to WT CARD11 
2





Figures and Figure Legends 
 
Figure 2.1: CARD11’s inhibitory domain comprises of multiple functional elements. 
Schematic representation of murine CARD11 protein with enlargement of the residues 
441-671 corresponding to CARD11’s inhibitory domain. Position and boundaries of four 
repressive elements, two activating elements and a single inducibility element within the 









Figure 2.2: CARD11’s inhibitory function consists of multiple regions with 
repressive function. (A) Schematic representation of intradomain ID deletions. (B) NF-
κB luciferase assay performed on stable CARD11 knockdown Jurkat T cells transfected 
with indicated murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml 
αCD28 for 5 hrs. Jurkat T cells stably expressing NT shRNA and CARD11 shRNA 
transfected without CARD11 rescue constructs were used as controls. (C) 293T 
expression assay using ng amounts of CARD11 intradomain ID deletion expression 
constructs transfected in (B) and blotted for anti-myc showed that all constructs are 









Figure 2.3: N-terminus of ID contains a repressive element. (A) Schematic 
representation of CARD11 ID deletion constructs analyzed. Portions of the inhibitory 
domain are sequentially added from the N-terminus of the ID. (B) NF-κB luciferase assay 
performed on stable CARD11 knockdown Jurkat T cells transfected with indicated 
murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. 
Jurkat T cells stably expressing NT shRNA and CARD11 shRNA transfected without 
CARD11 rescue constructs were used as controls. (C) 293T expression assay using ng 
amounts of CARD11 N-terminal ID addition expression constructs transfected in (B) and 










Figure 2.4: CARD11 RE1 maps to residues 441-493. (A) Schematic representation of 
CARD11 ID deletion constructs analyzed. Portions of the putative N-terminal repressive 
element are deleted from the C-terminus and then deleted from the N-terminus using the 
identified C-terminal boundary. The sequence of the minimal repressive element is 
shown. (B, D) NF-κB luciferase assay performed on stable CARD11 knockdown Jurkat T 
cells transfected with indicated murine CARD11 variants and stimulated with 1μg/ml 
αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing NT shRNA and 
CARD11 shRNA transfected without CARD11 rescue constructs were used as controls.  
(C) 293T expression assay using ng amounts of CARD11 C-terminal deletion expression 
constructs transfected in (B) and blotted for anti-myc showed that all constructs are 
expressed equivalently. (E) 293T expression assay using ng amounts of CARD11 N-
terminal deletion expression constructs transfected in (D) and blotted for anti-myc 










Figure 2.5: C-terminus of ID contains a novel activating element and a potent 
repressive element. (A) Schematic representation of CARD11 ID constructs analyzed. 
Portions of the inhibitory domain are sequentially added from the C-terminus of the ID. 
The sequence of the minimal activating element is shown. (B) NF-κB luciferase assay 
performed on stable CARD11 knockdown Jurkat T cells transfected with indicated 
murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. 
Jurkat T cells stably expressing NT shRNA and CARD11 shRNA transfected without 
CARD11 rescue constructs were used as controls. (C) 293T expression assay using ng 
amounts of CARD11 C-terminal addition expression constructs transfected in (B) and 









Figure 2.6: CARD11 RE4 maps to residues 617-641. (A) Schematic representation of 
CARD11 ID deletion constructs analyzed. Portions of the inhibitory domain are deleted 
from C- or N-terminus of the putative RE4 without affecting AE2. The sequence of the 
minimal repressive element is shown. (B, D) NF-κB luciferase assay performed on stable 
CARD11 knockdown Jurkat T cells transfected with indicated murine CARD11 variants 
and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably 
expressing NT shRNA and CARD11 shRNA transfected without CARD11 rescue 
constructs were used as controls. (C) 293T expression assay using ng amounts of the 
indicated CARD11 expression constructs transfected in (B) and blotted for anti-myc 
showed that all constructs are expressed equivalently. (E) 293T expression assay using ng 
amounts of the indicated CARD11 expression constructs transfected in (D) and blotted 










Figure 2.7: M1 and M2 abolish RE1 repressive function. (A) Schematic representation 
of CARD11 minimal RE1 and mutant variant constructs analyzed. (B) NF-κB luciferase 
assay performed on stable CARD11 knockdown Jurkat T cells transfected with indicated 
murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. 
Jurkat T cells expressing NT shRNA and stable CARD11 knockdown cells transfected 
without CARD11 rescue constructs were used as controls.  (C) 293T expression assay 
using ng amounts of CARD11 RE1 variant expression constructs transfected in (B) and 











Figure 2.8: Multiple mutations in RE4 disrupt its repression.  (A) Schematic 
representation of CARD11 RE4 and mutant variant constructs analyzed. (B, C) NF-κB 
luciferase assay performed on stable CARD11 knockdown Jurkat T cells transfected with 
indicated murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 
for 5 hrs. Jurkat T cells stably expressing NT shRNA and CARD11 shRNA transfected 
without CARD11 rescue constructs were used as controls. (D) 293T expression assay 
using ng amounts of CARD11 RE4 variant expression constructs transfected in (B and C) 








Figure 2.9: Internal regions of the ID include at least one additional repressive  
element. (A) Schematic representation of CARD11 ID C-terminal addition constructs in 
the context of mutating RE1 or CARD11 N-terminal addition constructs in the context of 
mutating RE4. (B, D) NF-κB luciferase assay performed on stable CARD11 knockdown 
Jurkat T cells transfected with indicated murine CARD11 variants and stimulated with 
1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing NT shRNA and 
CARD11 shRNA transfected without CARD11 rescue constructs were used as controls. 
(C) 293T expression assay using ng amounts of CARD11 C-terminal addition expression 
constructs in the context of mutating RE1 transfected in (B) and blotted for anti-myc 
showed that all constructs are expressed equivalently. (E) 293T expression assay using ng 
amounts of CARD11 N-terminal addition expression constructs in the context of 









Figure 2.10: CARD11 RE2 and RE3 share homologous sequences that abrogate 
repression when mutated. (A) Schematic representation of CARD11 ID N-terminal 
additions of two independent REs in the context of mutant RE4. The sequence of the two 
minimal repressive elements is shown. A schematic of RE2 and/or RE3 mutants and their 
sequence are also shown. (B) NF-κB luciferase assay performed on stable CARD11 
knockdown Jurkat T cells transfected with indicated murine CARD11 variants and 
stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing 
NT shRNA and CARD11 shRNA transfected without CARD11 rescue constructs were 
used as controls. (C) 293T expression assay using ng amounts of specified CARD11 
expression constructs transfected in (B) and blotted for anti-myc showed that all 









Figure 2.11: CARD11 ID encodes a second activating element. (A) Schematic 
representation of CARD11 ID AE1 and/or AE2 constructs analyzed. The sequence of the 
minimal AE1 is shown. (B) NF-κB luciferase assay performed on stable CARD11 
knockdown Jurkat T cells transfected with indicated murine CARD11 variants and 
stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing 
NT shRNA and CARD11 shRNA transfected without CARD11 rescue constructs were 
used as controls. (C) 293T expression assay using ng amounts of CARD11 AE 
expression constructs transfected in (B) and blotted for anti-myc showed that all 









Figure 2.12: CARD11’s inducibility element is embedded within activating 
element1. (A) Schematic representation of CARD11 ID internal deletion constructs 
analyzed. The sequence of the minimal IE is shown. (B) NF-κB luciferase assay 
performed on stable CARD11 knockdown Jurkat T cells transfected with indicated 
murine CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. 
Jurkat T cells stably expressing NT shRNA and CARD11 shRNA transfected without 
CARD11 rescue constructs were used as controls. (C) 293T expression assay using ng 
amounts of CARD11 internal deletion expression constructs transfected in (B) and 









Figure 2.13: Multiple mutations in multiple repressive elements are required to 
completely destroy inhibitory function. (A) Schematic representation of CARD11 full-
length quadruple RE mutant variants. Second site mutations M13 and M14 in RE1 are 
shown. (B) NF-κB luciferase assay performed on stable CARD11 knockdown Jurkat T 
cells transfected with indicated murine CARD11 variants and stimulated with 1μg/ml 
αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing NT shRNA and 
CARD11 shRNA transfected without CARD11 rescue constructs were used as controls. 
(C) 293T expression assay using ng amounts of CARD11 quadruple RE mutant 
expression constructs transfected in (B) and blotted for anti-myc showed that all 










Figure 2.14: Repressive elements act synergistically to repressive basal NF-κB 
activity. (A) Schematic representation of CARD11 full-length single, double or triple RE 
mutant variants. (B) NF-κB luciferase assay performed on stable CARD11 knockdown 
Jurkat T cells transfected with indicated murine single RE mutant CARD11 variants and 
stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing 
NT shRNA and CARD11 shRNA transfected without CARD11 rescue constructs were 
used as controls. (C) 293T expression assay using ng amounts of CARD11 single RE 
mutant variant expression constructs transfected in (B) and blotted for anti-myc showed 
that all constructs are expressed equivalently. (D) NF-κB luciferase assay performed on 
stable CARD11 knockdown Jurkat T cells transfected with indicated murine double RE 
mutant CARD11 variants and stimulated with 1μg/ml αCD3, 1μg/ml αCD28 for 5 hrs. 
Jurkat T cells stably expressing NT shRNA and CARD11 shRNA transfected without 
CARD11 rescue constructs were used as controls. (E) 293T expression assay using ng 
amounts of CARD11 double RE mutant variant expression constructs transfected in (D) 
and blotted for anti-myc showed that all constructs are expressed equivalently. (F) NF-κB 
luciferase assay performed on stable CARD11 knockdown Jurkat T cells transfected with 
indicated murine triple RE mutant CARD11 variants and stimulated with 1μg/ml αCD3, 
1μg/ml αCD28 for 5 hrs. Jurkat T cells stably expressing NT shRNA and CARD11 
shRNA transfected without CARD11 rescue constructs were used as controls. (G) 293T 
expression assay using ng amounts of CARD11 triple RE mutant variant expression 









Figure 2.15: All repressive elements work together to prevent Bcl10 association. (A-
C) HEK 293T cells transfected with the indicated myc-CARD11 variants in the absence 
of presence of FLAG-tagged Bcl10 were subjected to anti-FLAG co-
immunoprecipitation. Co-IP of FLAG-Bcl10 and myc-CARD11 WT or ID-deleted 









Figure 2.16: Multiple repressive elements control intramolecular binding. (A-C) 
HEK 293T cells were co-transfected with indicated Myc-CARD11variant and either 
FLAG-GST-ID or FLAG-GST expression constructs. Lysates were pulled down with 













Figure 2.17: Isolated repressive elements are sufficient to bind to other domains 
within CARD11. (A-D) GST pulldown of HEK 293T cells co-transfected with the 
following expression constructs: myc-CARD11 WT, single RE1 mutant and ΔID with 
FLAG-GST or FLAG-GST-RE14 (A); myc-CARD11 WT, single RE2 mutant and ΔID 
with FLAG-GST or FLAG-GST-RE24 (B); myc-CARD11 WT, single RE3 mutant and 
ΔID with FLAG-GST or FLAG-GST-RE34 (C); myc-CARD11 WT, single RE4 mutant 









Figure 2.18: Repressive elements 1, 2 and 3 bind to different domains of CARD11. 
(A-C) HEK 293T cells co-transfected with the indicated myc-CARD11 ΔID deletion 
variant and FLAG-GST or the following FLAG-GST-RE4 variants were subjected to 













Figure 2.19: Oncogenic CARD11 mutations disrupt binding to multiple ID 
repressive elements. (A-C) Indicated Myc-CARD11 ΔID oncogenic variants were co-
transfected with FLAG-GST, FLAG-GST-RE14 (A), FLAG-GST-RE24 (B), or FLAG-























CARD11 autoinhibition by its ID is essential for controlling intramolecular 
interactions, scaffolding function and downstream NF-κB activation. Exactly how the ID 
inhibits activity before antigen receptor engagement and triggers the transition into the 
active conformation is poorly understood. Our results revealed that the inhibitory domain 
actually contains multiple modulating elements that cooperatively control CARD11 
activity and output. Among these elements, four independent repressive elements act 
redundantly to keep CARD11 in the closed, inactive conformation and prevent Bcl10 
association. Each RE binds a unique set of intramolecular sites that partially overlap. 
Furthermore, RE inhibition is neutralized by a single, central inducibility element. The 
overall CARD11 activity is determined by the interplay between the previous elements 
and two newly identified activating elements. The lymphoma-associated CARD, LATCH 
and CC domain mutants manipulate this regulatory dynamic by undoing the effects of at 
least two ID REs. 
While the four REs were functionally and mechanistically redundant, they had 
unique properties. Aside from RE2 and RE3, there was very little sequence similarity 
among the REs in terms of length and amino acid composition (Figure 2.1). These 
differences most likely account for the different potencies of each RE (Table 2.4). 
Despite the fact that all four REs were capable of inhibiting Bcl10 binding and 
maintaining intramolecular contacts, RE1 appeared to be the most effective for both. In 
fact, all three other REs needed to be mutated to see appreciable binding to Bcl10 (Figure 
2.15C). Though all four REs were sufficient to bind the remaining CARD11 domains, 




different domains to mediate this binding (Figure 2.18). Thus, each RE had a distinct 
repressive profile. 
Though previous studies only implicated the CARD, L1 and CC in ID binding, 
we found an additional requirement of the GUK domain to bind RE1 (Figure 2.18A) 
(Chan et al., 2013; McCully and Pomerantz, 2008). Our results also implicated the L3 
and SH3 domains as inhibitors of RE1 binding. This result is not surprising given 
evidence in the literature of the SH3 domains of other MAGUK family members binding 
intramolecularly with their GUK domain and possibly occluding GUK accessibility 
(McGee and Bredt, 1999; Pan et al., 2011; Qian and Prehoda, 2006). It is generally 
thought that GUK domains are important for protein-protein interactions; however, little 
is understood about GUK domain function in CARD11 activation (Li et al., 2002; Oliva 
et al., 2012). Previous studies showed the GUK domain was required for Ag-mediated 
NF-κB activation and for constitutive PP2A constant regulatory subunit A (PPP2R1A) 
binding (Eitelhuber et al., 2011; Pomerantz et al., 2002). Interestingly, PP2A negatively 
regulates CARD11-mediated NF-κB activity by dephosphorylating S657 (Eitelhuber et 
al., 2011). Hence, it is possible that RE1 mediates PP2A binding to the GUK domain or 
regulates the inhibitory function of PP2A. Similarly, RE1 may regulate the negative 
regulator PKCδ, which binds the MAGUK of CARD11 (Liu et al., 2012). Because 
previous studies also showed that the adapter protein ADAP binds the MAGUK moiety 
of CARD11 to activate downstream NF-κB activity in T cells, RE1 could instead 
compete with ADAP and lead to repression (Medeiros et al., 2007). Further studies are 




      One intriguing question our studies tried to address is how intramolecular 
interactions are related to Bcl10 binding. It is possible that disruption of RE binding must 
precede Bcl10 binding, and the two repressive mechanisms are separable. Alternatively, a 
decrease in RE binding may cause obligatory Bcl10 binding without a second regulatory 
step. A third possibility is that Bcl0 binding competes for the same RE binding sites and 
displaces the RE. With the exception of the CARD11 double mutants variants where RE1 
is WT, all RE mutant variants that disrupt intramolecular binding are also able to bind 
Bcl10 (Figure 2.15 and Figure 2.16). Although in most cases there is a negative 
correlation between intramolecular binding and Bcl10 association, this result suggests 
that disrupting RE binding may not automatically dictate Bcl10 binding. We cannot 
exclude the possibility that the differences we see may reflect the limitations of our assay. 
Nevertheless, it strongly supports the need for further validation and exploration into 
distinguishing between the two mechanisms of repression. 
Surprisingly, RE potency did not correlate with its ability to control Bcl10 
binding or its ability to bind internally to other CARD11 domains. Though RE1 was the 
second strongest repressor, it had the greatest effect on Bcl10 association and 
intramolecular binding (Table 2.4, Figure 2.15 and Figure 2.16). To reconcile this 
difference, we propose that the specific repression of each RE is dictated by its 
intramolecular binding targets, whereby disruption to one domain has a greater effect on 
activity than disruption to another domain. Even so, because of the extremely weak 




and cannot claim that it has a unique target binding profile that accounts for its repressive 
potency. Therefore, we cannot eliminate alternative methods of RE repression. 
There are multiple possible alternative methods of RE repression. One simple way 
is that the REs prevent association with an activating co-factor that is more correlative 
with NF-κB activity. It is not likely that this protein is a previously identified ID-
regulated interactor of CARD11, such as MALT1, TRAF6, the IKK proteins, TAK1 or 
Caspase-8, because other hyperactive CARD11 variants did not spontaneously associate 
with them (Chan et al., 2013; Lamason et al., 2010). Candidate CARD11-interacting 
proteins that activate signaling that currently exist in the literature include ADAP, 
calmodulin-dependent protein kinase II (CaMKII), HPK1, aryl hydrocarbon receptor 
(AHR) interacting protein (AIP), stress-induced-phosphoprotein 1 homology and U-box 
containing protein 1 (STUB1) and Akt (Brenner et al., 2009; Cheng et al., 2014; Ishiguro 
et al., 2006; Medeiros et al., 2007; Narayan et al., 2006; Schimmack et al., 2014; Wang et 
al., 2013). Aside from preventing the association of these adaptors, the REs could 
associate with other proteins that inactivate the above signaling cofactors. These 
repressors may act by directly inhibiting CARD11 or other members of the signaling 
pathway. Potential negative regulator candidates include PP2A, PKCδ or casein kinase-2 
interacting protein-1 (CKIP-1) (Eitelhuber et al., 2011; Liu et al., 2012; Sakamoto et al., 
2014). Interestingly, CK1α is a bifunctional regulator of CARD11-mediated signaling 
that requires the ID domain for binding (Bidere et al., 2009). In fact, CK1α 
phosphorylation of S620 in RE4 was shown to be important for downregulating TCR 




results in a modest affect on repression, it may support a partial contribution of CK1α 
phosphorylation in RE4 repression. Therefore, it would be interesting to see if RE4 was 
sufficient to bind CK1α and if CK1α was necessary for RE4 repression.  
We also report here the serendipitous discovery of two novel activating elements 
that were able to induce CARD11-mediated NF-κB activation to previously 
unappreciated levels (Figure 2.11). Despite limited similarity between the two AEs, both 
surprisingly share a PKCθ or PKCβ phosphorylation site (Matsumoto et al., 2005; 
Sommer et al., 2005). Both phosphorylation events have been shown to be triggered by 
lymphocyte stimulation and are required for downstream activation, but our studies may 
implicate a different role of these sites in the absence of Ag receptor engagement. Along 
these same lines, AE1 actually contains multiple serine and threonine residues that may 
contribute to the activating function. Some of these residues have previously been 
identified as phosphorylation sites after stimulation (Brenner et al., 2009; Matsumoto et 
al., 2005; Shinohara et al., 2007). So, it would be interesting to investigate their role in 
activation function as well. The outstanding question remains as to what role these AEs 
play in normal lymphocyte signaling. Why would these cells evolve the need to incur 
such robust activation? We anticipate this finding to open new and exciting avenues of 
studies into lymphocyte regulation. 
The last functional element we identified, the inducibility element, was defined as 
the minimal region of the ID needed to induce NF-κB activation downstream of αCD3 
and αCD28 signaling. This 25 amino acid element contains serine residues S563, S564, 




2009; Matsumoto et al., 2005; Shinohara et al., 2007; Sommer et al., 2005). 
Unexpectedly, we discovered that deletion of S649 and S657 had no effect on NF-κB 
signaling (Figure 2.2B). There is some controversy in the literature on the exact functions 
of these residues. With regards to S649, it was originally identified as a possible PKCθ 
substrate, but was dispensable for NF-κB activation downstream of PMA and αCD3 
(Matsumoto et al., 2005; Sommer et al., 2005). It was later detected by a phospho-S649-
specific antibody after TCR stimulation and found to negatively regulate BCR 
stimulation independently of PKCβ (Moreno-Garcia et al., 2009). More recently, it was 
discovered that S649 is an Akt substrate (Cheng et al., 2014). When mutated by itself, 
S649 was activating, but when combined with S657, it cooperatively dampened NF-κB 
signaling (Cheng et al., 2014). This implies some interplay between S649 and S657 
function and may explain why we see no effect of S649 deletion. The literature on S657 
is more consistent as two groups identified it as a potential PKCθ substrate downstream 
of Ag receptor signaling that, when mutated, decreased NF-κB activation by about two 
fold (Matsumoto et al., 2005; Sommer et al., 2005). Our data contradicts their findings 
and necessitates further inquires to resolve this discrepancy. 
 With seven regulatory elements encoded within the short 231 amino acids of the 
ID, we uncovered a highly modular method of controlling signaling output. We must now 
amend the previous, simple model of ID function by saying that CARD11 activity is 
determined by the interplay of all the functional elements. This includes all possible 
IE:AE, IE:RE, and AE:RE relationships. Future studies should reveal the nuances of 




could reveal whether AEs require another regulatory step before becoming active. Our 
current data holds some clues about RE and AE relationships. For example, RE2 or RE3 
was sufficient to completely repress AE2, but not could not fully repress AE1 and AE2 
together (Figure 2.10B and Figure 2.14F), suggesting that different REs have different 
repressing potentials for each AE. One of the most intriguing relationships is the one 
between the IE and AE1 because the IE is completely embedded in AE1. It is unclear if 
the two elements utilize separate mechanisms to exert their functions. If they are not 
separable units, then does AE1 determine IE function or vice versa? Overall, we expect 
loss-of-function mutations in all seven elements would result in the activity levels of 
ΔID. 
Finally, the discovery of redundant REs within the ID suggests that the ID is 
highly evolved to prevent the occurrence of spontaneous oncogenic mutations. This is 
especially important in light of the previously unappreciated potential for CARD11-
mediated NF-κB activation (Figure 2.11B and Figure 2.13B). Even the most hyperactive 
lymphoma-associated CARD11 mutations are only about 10% as active as the quadruple 
RE mutant, suggesting that these variants are still considerably repressed (Chan et al., 
2013; Lamason et al., 2010). The level of activation of several characterized CARD, 
LATCH and CC mutants was on par with the simultaneous mutations of two REs (Table 
2.4). Our binding data is consistent with the notion that lymphoma-associated CARD11 
mutation do not completely obstruct all RE function (Figure 2.19). Hence, we concluded 




disrupting binding to at least two REs. Furthermore, the RE redundancy provides a 
satisfying explanation for the lack of oncogenic mutations in the ID domain.  
To our knowledge, this is the first study showing multiple functional elements 
within CARD11’s inhibitory domain. It uncovers a highly modular mechanism of 
controlling both CARD11 and downstream Ag receptor activity. Furthermore, this may 
be the first in-depth characterization of an inhibitory domain whose activity is determined 
by so many regulatory components. It remains to be seen if this method of regulation is 
adopted by other ID-containing proteins or if this is specific to CARD11. Either way, our 
story adds a new facet to the already complex network of lymphocyte regulation and 
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